Wouter Joustra is a General Partner at Forbion, where he is responsible for deal origination, general portfolio management and divestment strategies, and focuses on Forbion’s Growth Opportunities Funds, which concentrates on investing in late-stage life sciences companies. Prior to joining Forbion in 2019, Mr. Joustra was a Senior Trader and Executive Board member of the Life Sciences franchise at Kempen, a European boutique investment bank. He has served on the boards of a range of high-growth biotech companies, including Gyroscope Therapeutics, VectivBio, and Aiolos Bio through their respective successful acquisitions by various multinational pharmaceutical companies. In addition to Vor Bio, he also serves on the Board of Directors of VectorY Therapeutics, NewAmsterdam Pharma N.V., Beacon Therapeutics, Navigator Medicines, and Verdiva Bio. Mr. Joustra holds an MSc in business administration and a BSc in international business and management from the University of Groningen.
